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Abstract 
Background: Pneumonia is the leading killer among all infectious diseases worldwide. Though treatable, it often 
results in high mortality and morbidity therefore putting pressure on available health resources. The best 
intervention for pneumonia is prevention through vaccination. 
Objective. To determine pneumococcal vaccine coverage among infants between 4-12 months in Nyamira County 
Methods: A cross sectional design was used in this study. Using questionnaires. Caregivers were interviewed and 
a checklist was used to review the vaccination records. Data was analyzed using descriptive statistics and 
inferential statistics. 
Results: The results indicated that coverage of 82.5% for PCV 10 vaccine is below the recommended 90%. 
Caregivers were predominantly female, 97% and in informal employment. Among the demographic factors of the 
cohort, level of education was found to be statistically significant with p values of 0.029 as calculated using 
Fischer’s Exact. Care Givers were asked whether they had other children that were below 5 years so as to determine 
whether their previous experience with their children made any impact on the vaccine coverage. This demographic 
factor was also found to be significant with a P value of 0.019 as calculated using Chi Square.  and the number of 
other children Caregivers had (besides the infant being studied) that were below 5 years were found to and 
respectively. 
Conclusion and Recommendations: Coverage of pneumococcal vaccine in Borabu Sub-County, Nyamira 
County was (82.5%), still below the internationally recommended target of 90%. Uptake of PCV 10 vaccine was 
found to be influenced by Knowledge about the PCV 10 vaccine, level of education of Caregivers and the age of 
children that Caregivers had who were below 5 years. The coverage of PCV 10 vaccine in Borabu Sub County in 
Nyamira County can be enhanced by increasing knowledge of Caregivers on PCV 10 vaccine and by increasing 
compliance to the vaccination schedule. This can be done through various channels such as use of mobile phone-
based reminders and community sensitization campaigns. A study can be done to identify effective interventions 
for delivering health education about pneumococcal vaccine in rural populations. In addition, interventional studies 
may be done to test effectiveness of reminder systems on immunization uptake. 
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Background 
Pneumonia is a lower respiratory tract infection that affects one or both lungs and is one of the leading causes of 
death in children below 5 years worldwide and a leading killer among all infectious diseases. It is most prevalent 
in South Asia and sub-Saharan Africa (WHO, 2016). It can be prevented through immunization, proper nutrition 
and management of environmental factors. While the bacterial infection can be treated with antibiotics, only a 
third of the children who get sick are able to access the antibiotics due to various reasons including cost. Bacterial 
Pneumonia is caused by Streptococcus pneumonia and may result in invasive pneumococcal diseases (IPD) such 
as bacteraemia, meningitis and bacteremic pneumonia, or in non-IPD, such as pneumonia, sinusitis and Otitis 
media (McClure, Ford, & Wilson, 2006). Children younger than 5 years are at highest risk of both IPD and non-
IPD. Preventive measures must therefore be provided at the earliest age possible because the vulnerability is 
highest at the young age.  
One of the vaccines that are available against pneumonia is PCV-10 vaccine; a ten-valent vaccine that targets 
10 strains of S. pneumonia that cause IPD; this form of pneumonia is the most fatal. The vaccine has demonstrated 
100% Efficacy against IPD (Tregnaghi et al., 2014). 
Compared with the other vaccines available for childhood vaccination, PCV is one of the vaccines whose 
coverage remains low. By 2017, PCV had been introduced to 135 countries and the global coverage was estimated 
at 44% compared with DPT at 90% in 123 countries, (WHO, 2018). Sub-Saharan Africa is one of the regions 
where the coverage of PCV remains low achieving coverage less than 60% as indicated by (WHO, SAGE, 2017). 
The recommended routine vaccination of PCV is either three doses with DPT or 2 doses before 6 months of age, 
plus booster dose at 9-15 months of age, (WHO, 2018). Kenya has adopted the former routine. 
Immunization coverage is critical as a determinant of the number of children that can be saved from the 
infections. Since introduction, 190,000 deaths have been averted, (WHO, 2017); the more reason why uptake of 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online)  
Vol.11, No.22, 2020 
 
2 
PCV 10 vaccine in Kenya is critical. In Kenya, six per 1000 deaths in under five were caused by pneumonia 
contributing to 15% of all child deaths in 2018, (Mugo, 2020). Pneumonia was identified as the leading killer 
disease in 2012 ahead of malaria with 19,011 cases, accounting for 10.9% deaths (Kenya National Bureau of 
Statistics, 2013). In addition, “Statistics from the Ministry of Public Health and Sanitation indicate that one in 
every five deaths in the country is attributed to pneumonia” (University of Nairobi, 2013).  
In 2013, Nyamira County’s leading cause of death was pneumonia different from the national, which was 
HIV/AIDs, (Department of Health Services, 2014). In addition, under five leading cause of death was reported as 
pneumonia (KNBS, 2015) making this an important county of study. In 2018, while the national under five 
mortalities due to pneumonia was six per 1000, Nyamira was among the 12 counties with more than double the 
rate: 12-14 deaths per 1000, (Mugo, 2020). Despite the availability of the vaccine (PCV 10) for prevention of the 
disease, the uptake has continued to decline in the county compared with national. The national Full Immunization 
Coverage (FIC) for children below one year decreased by 3% between 2016 and 2017 in Kenya while in Nyamira 
County it decreased by 23% between the same period, (Kenya National Bureau of Statistics, 2018). Similarly, the 
coverage of PCV 10 was even lower in Borabu Sub County compared to the County. In 2017, the PCV 10 coverage 
in the County was 64% while Borabu Sub County was 61% for the third dose, (County Government of Nyamira, 
2018). In Borabu Sub-County, coverage of PCV 10 decreased from 83% in 2013 to 61% in 2017 (County 
Government of Nyamira, 2018). 
In Kenya, an efficacy study in Kilifi established that PCV 10 results in an estimated 42.7% reduction in 
pneumococcal disease episodes and a 6.1% reduction in childhood deaths, (WHO, 2015). PCV 10 reduces 
pneumococcal bacterium in the population by two thirds therefore offering not just individual protection but also 
herd immunity (Hammitt, 2014). It is therefore a key pillar in reduction of pneumonia infections and deaths. On 
the other hand, S. pneumonia, one of the causes of pneumonia has shown resistance to antibiotics used in treatment. 
Reducing the number of infections will help preserve the antibiotics. In Kenya, few studies exist in the country 
that could inform the intervention on PCV 10 vaccine uptake. 
 
Methods and Materials. 
Study Area, Period and Design 
The study location was Borabu Sub-county in Nyamira County. A cross sectional study design was applied to 
assess the PCV vaccination uptake among Caregivers between February 1st and February 27th 2020.  
 
Study Population 
Caregivers of children between the ages of 4 to 12 months. 
 
Sample size and sample size determination 
The Statistical Cochran equation was applied to determine sample: size n0=Z2pq/e2 Where; n0= sample size, Z is 
the abscissa of the normal curve that cuts off an area α at the tails; at the desired confidence level of 95% Z= 1.96; 
p is the estimated proportion of an attribute that is present in the population; p = 0.67 (percentage of infants between 
4-12 months that are likely to be immunized based on administrative immunization coverage for 2017 at 67%), 
(County Government of Nyamira, 2018).  
 
Sampling Technique 
Nyamira County and Borabu Sub County were purposively selected for this study due to the low PCV 10 
immunization coverage (County Government of Nyamira, 2018). Simple random sampling was used for the wards, 
the Community Health Units (CHU) and the households within the Sub County. Community Health Extension 
Workers (CHeWs) assigned to the respective units helped in random sampling of the households within each 
community unit for Caregivers of 4-12 months’ infants. For households with more than one Caregiver of 4-12 
months’ infant, simple random sampling was applied.  
 
Eligibility Criteria  
• Inclusion criteria 
All resident Caregivers of infants between 4 to 12 months that were in Borabu sub county between February 1st 
and February 27th 2020 of June 1 to June 30, 2018. 
• Exclusion Criteria  
Caregivers of infants between 4 to 12 months that had visited the Sub County and those that did not consent to the 
study and were excluded. 
 
Data collection instrument  
The data was collected by use of interviewer-administered questionnaires. The research assistants were taken 
through basic training on interviewing techniques to enhance validity of the data collected. A checklist was used 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online)  
Vol.11, No.22, 2020 
 
3 
to obtain objective data on the child’s immunisation status. 
 
Data Quality Assurance  
Before actual implementation of the study, a pre-test of the questionnaires was done on a sample of households 
selected randomly from Bosamaro ward in Nyamira South Sub County, Nyamira County to ensure that the 
questionnaire produced similar results on repeated interviews. Any questions that were generating varied responses 
on repeated administration were revised to enhance consistency. The questionnaires were subjected to reviews by 
experts in child health to ascertain the content validity of the questions in assessing immunization status of the 
eligible infants and knowledge of caregivers about the vaccine. Data collected was first checked for completeness 
and accuracy then analysis was conducted using descriptive and inferential statistics.  
 
Ethical Considerations  
The study attained approvals from the relevant bodies including, Kenyatta University Ethical Review Committee 
and the National Commission for Science and Technology (NACOSTI). Permission to collect data was also sought 
from the county administrative offices before commencement of fieldwork. Privacy and confidentiality of the 
information from the respondents was ensured by having all interviews done in private. Before participation in the 
study, all respondents signed an informed consent form after being informed of the purpose and their expected 
roles in the study. The questionnaires were anonymous. 
 
Results 
The sample predominantly comprised of females (96.8%, n=349) and only 3.2 % were male (Table 1.1). The 
median age of children between 4 to 12 months was 9 months. Most caregivers had some form of education. The 
number of caregivers with secondary level of education was the highest at 57.9% followed by primary at 32.1% 
while the university level had the least population at 2%, (Table 1.1). Most caregivers were in informal 
employment (90.49%) and only 6.05% were formally employed, (Table 1.1). The level of education of caregivers 
was found to be significant in terms of association with the vaccine uptake; (P=0.029) (Table 1.2). 
Table 1.1: Socio-demographic characteristics of the Caregivers  
Characteristic  Frequency % 
Sex ( n=348) 
  Men  11 3.2 
  Female  337 96.9 
Education (n=349) 
None 1 0.39 
Primary  112 32.1 
Secondary 202 57.9 
College  27 7.7 
University 7 2 
Occupation (n=347) 
 Unemployed 12 3.46 
  Informally employed 314 90.49 
  Formally employed 21 6.05 
Number of other children the Caregiver had that were below 5 years (n=351) 
1-3 334 95.16 
> 3 17 4.84 
Similarly, the number of other children that the Caregivers had that were below 5 years was also significantly 
associated with the vaccine uptake (χ²=29; df=1; p=0.019) (Table 1.2). a higher percentage (95.16) of Care Givers 
that had other children between 1 and 3 years (besides the infant being studied) vaccinated their children. This 
compares to only 4.84% of the Care Givers with children >3 years but below 5 years (besides the infant being 
studied). The age and occupation of the caregivers were not statistically significant in terms of association with 
the vaccine uptake with p values of 0.28 and 0.30 respectively, (Table 1.2). the age of the Caregiver and their 
occupation did not determine whether they took the infants for vaccination or not. 
  
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online)  
Vol.11, No.22, 2020 
 
4 
Table 1.2: Bivariate analysis of association of socio-demographic factors to vaccine uptake 
Variable  Pneumococcal vaccination 
uptake 
 Test Test 
Significance 





Totals   
Level of education      
   None 1(100) 0 (0) 1 (100) Fisher’s 
exact 
0.029* 
   Primary 27 (24.11) 85(75.89) 112 (100) 
   Secondary 31 (15.35) 171(84.65) 202 (100) 
   College 2 (7.41) 25 (92.59) 27 (100) 
   University 0 (0) 7 (100) 7 (100) 




 t-test 0.31 
Occupation       
Unemployed  0 (0) 12 (100) 12 (100) Fisher’s 
exact 
0.28 
Informally   employed 58 (18.47) 256 (81.53) 314 (100) 
Formally employed 3 (14.29) 18 (85.71) 21 (100) 
Number of other children 
below 5 years 




  1-3 55 (16.47) 279 (83.53) 334 (100) 
>3 6 (40.00) 9 (60.00) 15 (100) 
 
Coverage of pneumococcal vaccine among infants between 4 to 12 months 
The objective of this study was to determine pneumococcal immunization coverage of infants between 4 to 12 
months. Data on the vaccination uptake was obtained by first asking the caregivers whether their children had been 
vaccinated, and then going further to verify the details from child’s immunization card. The overall uptake of 
pneumococcal vaccine was dichotomized into fully vaccinated (all three doses given) and not fully vaccinated 
(less than three doses).  
A breakdown of the number of pneumococcal vaccine doses received and the overall vaccine uptake is 
presented in table 1.3. Overall, a majority (82.5%,) of the infants had been fully vaccinated for PCV 10 while 
17.48% were not fully vaccinated, (Table 1.3). Of the children that were not fully vaccinated (6%) had received 
none of the three vaccine doses that are recommended, 4.3% had received only one dose and 6.88% had received 
two doses (Table 1.3). Among the infants who had been partially vaccinated, (62%) of them received only two 
doses while 38% received only one dose among the not fully immunized children (Figure 1.2).  
Table 1.3: Pneumococcal vaccine uptake 
Variable Frequency 
Number of PCV vaccine doses received (n=349) 
None         22 (6.3%) 
One dose 15 (4.3%) 
Two doses          24 (6.88%) 
Three doses         288 (82.52%) 
PCV uptake n=(349) 
Not fully vaccinated  61 (17.48%) 
Fully vaccinated         288 (82.52%) 
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Figure 1.1: Proportion of doses given to children not fully vaccinated. 
 
 
Figure 1.2: Partially vaccinated children 
 
 
Conclusion and Recommendations 
Coverage of pneumococcal vaccine in Borabu Sub-County, Nyamira County was (82.5%), still below the 
internationally recommended target of 90%. Based on the findings from this study it is recommended that in order 
to increase vaccine coverage, adherence to the vaccination schedule should be enhanced with reminders and 
increased capacities of lower level health facilities. The Health system should consider mass sensitization 
campaigns to increase awareness and knowledge about the PCV 10 vaccine in Nyamira County. This study 
presents opportunity for further research one of which would be to identify effective interventions for delivering 
health education about pneumococcal vaccine in rural populations. Interventional studies may also be done to test 
effectiveness of reminder systems on immunization uptake.  
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